| Name | Title | Contact Details |
|---|
PCHS of Alaska (Peninsula Community Health Services) is a Soldotna, AK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Highland Park Healthcare Inc is a Highland Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
St. Luke`s, a regional health care system, offers a comprehensive continuum of care serving the 17-county region of northeastern Minnesota, northwestern Wisconsin and the Upper Peninsula of Michigan. The system includes St. Luke`s Hospital in Duluth, Minnesota, Lake View Hospital in Two Harbors, Minnesota, and 11 primary and 27 specialty clinics. Primary care clinics are located in Duluth, Hermantown, Hibbing, Two Harbors, Mountain Iron and Silver Bay, Minnesota, and Ashland and Superior, Wisconsin. Urgent care and Q Care express medical services are also available. St. Luke`s is designated by the American College of Surgeons and the state of Minnesota Department of Health as a Level II trauma center. St. Luke`s Regional Cancer Center offers treatments including Stereotactic Radiosurgery (SRS) and radiation oncology. St. Luke`s Regional Heart Center includes cardiology, cardiothoracic surgery, cardiac rehab services and catheterization lab. Other specialties include obstetrics, gynecology, plastic surgery, pulmonary medicine, allergy, neurosurgery, dermatology, endocrinology, gastroenterology, infectious disease, surgery, occupational health, orthopedics and sports medicine, pediatrics, physical medicine and rehab, rheumatology, psychiatry, urology, hospice and home care. With the University of Minnesota Duluth Medical School, St. Luke`s conducts clinical research in the areas of cancer, lung and heart disease through the Whiteside Institute for Clinical Research.
Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercialises a range of CBD-based products under the Dr. AnnaRx™ and Medspresso™ brands.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.